ResMed, Inc.

Equities

RMD

US7611521078

Market Closed - Nyse Other stock markets 21:00:02 09/12/2025 GMT			5-day change	1st Jan Change
246.52 ^USD	-1.41%		-1.73%	+7.80%

08:24pm	Resmed Insider Sold Shares Worth $1,254,796, According to a Recent SEC Filing	MT
01:42am	Shares of Resmed Fall After Securing FDA Clearance for a Device Recommending Personalized Comfort Settings	MT

Transcript : ResMed Inc., Q1 2026 Earnings Call, Oct 30, 2025

Published on 10/30/2025 at 10:50 pm GMT - Modified on 11/07/2025 at 03:23 am GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Q1 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin. I'll be your operator for today's call. [Operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about ResMed, Inc.

08:24pm	Resmed Insider Sold Shares Worth $1,254,796, According to a Recent SEC Filing	MT
01:42am	Shares of Resmed Fall After Securing FDA Clearance for a Device Recommending Personalized Comfort Settings	MT
12-08	ResMed Receives FDA Clearance for AI-Powered Device to Personalize Sleep Apnea Therapy	MT
12-08	Resmed, Inc. Receives FDA Clearance for Personalized Therapy Comfort Settings, to Be Marketed as Smart Comfort	CI
12-04	Resmed Insider Sold Shares Worth $502,940, According to a Recent SEC Filing	MT
12-02	LivaNova PLC Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea, Effective December 1, 2025	CI
11-25	ResMed Inc. Announces Not Seek Re-Election of Richard Sulpizio to the Board of Directors, Effective November 19, 2025	CI
11-25	UK financial sector makes slow progress on preparations for new settlement system	RE
11-11	ResMed Insider Sold Shares Worth $2,000,773, According to a Recent SEC Filing	MT
11-05	ResMed CFO Sells Shares	MT
11-05	ResMed CFO Buys, Sells Shares	MT
11-04	Resmed Insider Sold Shares Worth $742,620, According to a Recent SEC Filing	MT
11-03	ResMed CFO Sells Shares	MT
11-03	ASX Biggest Losers	MT
11-03	ASX Midday Sector Update: Information Technology Stocks Rise, Healthcare Down	MT
10-31	Baird Adjusts Price Target on ResMed to $300 From $320	MT
10-31	Jefferies & Co Adjusts ResMed Price Target to $285 From $290	MT
10-31	Wells Fargo Adjusts ResMed Price Target to $265 From $280	MT
10-31	Wolfe Research Adjusts ResMed Price Target to $225 From $215	MT
10-31	Morgan Stanley Adjusts ResMed Price Target to $305 From $304	MT
10-31	Mizuho Adjusts Price Target on ResMed to $300 From $310	MT
10-31	KeyBanc Adjusts Price Target on ResMed to $299 From $298	MT
10-31	RBC Lifts Price Target on ResMed to $303 From $300, Keeps Outperform Rating	MT
10-31	Morgan Stanley Lifts Price Target on ResMed to $305 From $304, Keeps Overweight Rating	MT
10-31	Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014.	CI